Bruserud Øystein, Reikvam Håkon
Acute Leukemia Research Group, Department of Clinical Science, University of Bergen, 5007 Bergen, Norway.
Section for Hematology, Department of Medicine, Haukeland University Hospital, 5009 Bergen, Norway.
Cells. 2025 Sep 18;14(18):1461. doi: 10.3390/cells14181461.
Nucleoporin 214 (NUP214) is a component of the nucleopore molecular complex, but in addition to this role in nucleocytoplasmic transport it is also involved in the regulation of gene transcription/translation, intracellular signaling, cell cycle progression and programmed cell death. Several uncommon translocations associated with acute myeloid leukemia (AML) involve the gene, and the corresponding fusion proteins are involved in leukemic transformation. First, the t(6;9) translocation encodes the DEK-NUP214 fusion protein; this translocation is seen in 1-2% of AML patients and is associated with an adverse prognosis that is improved by allogeneic stem cell transplantation. Second, the fusion gene is less common in AML and is formed either by del(9)(q34.11q34.13) or a balanced t(9;9)(q34;q34). This AML variant shows several biological similarities with the variant, but the possible prognostic impact of this fusion protein is not known. Finally, the and especially the fusions are very uncommon, and only a few case reports have been published. In this article, we review the functions of the genes/proteins formed by these fusion genes, the available studies of molecular mechanisms and biological functions for each fusion protein, the characteristics of the corresponding AML cells, the clinical characteristics of these patients and the possible prognostic impact of the fusion genes/proteins.
核孔蛋白214(NUP214)是核孔分子复合物的一个组成部分,但除了在核质运输中发挥这一作用外,它还参与基因转录/翻译的调控、细胞内信号传导、细胞周期进程和程序性细胞死亡。几种与急性髓系白血病(AML)相关的罕见易位涉及该基因,相应的融合蛋白参与白血病转化。首先,t(6;9)易位编码DEK-NUP214融合蛋白;这种易位见于1%-2%的AML患者,与不良预后相关,而异基因干细胞移植可改善这种预后。其次,该融合基因在AML中较少见,由del(9)(q34.11q34.13)或平衡的t(9;9)(q34;q34)形成。这种AML变异型与该变异型表现出一些生物学相似性,但这种融合蛋白可能的预后影响尚不清楚。最后,该融合尤其是该融合非常罕见,仅发表了少数病例报告。在本文中,我们综述了这些融合基因形成的基因/蛋白的功能、每种融合蛋白的分子机制和生物学功能的现有研究、相应AML细胞的特征、这些患者的临床特征以及融合基因/蛋白可能的预后影响。